

CV Date	10/12/2021
---------	------------

## Part A. PERSONAL INFORMATION

First Name *	Jesus María		
Family Name *	Paramio González		
Sex *	Male	Date of Birth *	18/02/1961
ID number Social Security, Passport *	2199602C	Phone Number *	(34) 914962517
URL Web	http://rdgroups.ciemat.es/web/oncomol/		
Email Address	jesusm.paramio@ciemat.es		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0001-7520-3177	
	Researcher ID	M-8482-2014	
	Scopus Author ID	6701734556	

\* Mandatory

## A.3. Education

Degree/Master/PhD	University / Country	Year
Ciencias (Biología)	Universidad Autónoma de Madrid	1992

## Part B. CV SUMMARY

Author of 137 articles in international scientific journals (Pubmed) and 8 book chapters. H index 38 (WOS) 44 (GoogleScholar) 40 (Researchgate). Of these, 48 articles in first Decile plus 69 in first quartile, 10 as a first author and 68 as corresponding (or co-corresponding) author.

Accumulated IF=1096 (8 citations/article as average), average citations 27.2 /article. Inventor of six patents, 85 invited plenary or invited conferences, Organizer of 7 International meetings, and chair for 12 different sessions

Participant in 34 (19 As PI) Research Grants (National and International) obtained in competitive concurrence. Participate in 7 industry-oriented clinical trials and studies (in three of them as Co-PI), Supervisor of 23 PhD and 17 MSc theses for different Spanish and international Universities.

Grant reviewer for multiple national and international agencies.

Editorial board member of Molecular Carcinogenesis, Molecular Cancer, PlosOne, Clinical and Translational Oncology, International Journal of Molecular Sciences.

Member of different national and international professional societies, including membership of the Executive Board of the Spanish Cancer Research Association (ASEICA) (2014-2018) and the secretariat of the Spanish Federation of Oncology Societies (FESEO) (2017-19).

## Part C. RELEVANT ACCOMPLISHMENTS

### C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- Scientific paper.** Segovia, Cristina; San Jose-Eneriz, Ederne; Munera-Maravilla, Ester; et al; Paramio, Jesus M. (AC). (28/28). 2019. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression NATURE MEDICINE. 25. ISSN 1078-8956. WOS (7)
- Scientific paper.** C; FX; F; et al; JM (AC); M. (16/17). BlaDimiR: A urine-based miRNA score for accurate bladder cancer diagnosis and follow-up Molecular Cancer. in press.

- 3 **Scientific paper.** IA; A; C; et al; L. (12/13). Genomic landscape and Immune-related gene expression profiling of 2 Epithelial Ovarian Cancer after Neoadjuvant chemotherapy Precision Oncology. Nature. in press.
- 4 Carvalho, Sandra; Abreu, Catarina M.; Ferreira, Dylan; et al; Oliveira, Marta I.2020. Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies FRONTIERS IN ONCOLOGY. 10. ISSN 2234-943X.
- 5 Lorenzo-Martin, L. Francisco; Fernandez-Parejo, Natalia; Menacho-Marquez, Mauricio; et al; Bustelo, Xose R.2020. VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma NATURE COMMUNICATIONS. 11. ISSN 2041-1723. WOS (1)
- 6 Font Pous, Albert; Climent Duran, Miguel Angel; Duran, Ignacio; et al; Castellano, Daniel E.2019. A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.JOURNAL OF CLINICAL ONCOLOGY. 37. ISSN 0732-183X.
- 7 de Velasco, Guillermo; Duenas, Marta; Bernardini, Alejandra; et al; Castellano, Daniel E.2019. Association of immune gene expression profiling with vinflunine clinical benefit in metastatic urothelial cancer (mUC).JOURNAL OF CLINICAL ONCOLOGY. 37. ISSN 0732-183X.
- 8 Rubio, Carolina; Martinez-Fernandez, Monica; Segovia, Cristina; et al; Paramio, Jesus M. (AC). (25/25). 2019. CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status CLINICAL CANCER RESEARCH. 25. ISSN 1078-0432. WOS (9)
- 9 Lazaro, Sara; Perez-Crespo, Miriam; Lorz, Corina; et al; Paramio, Jesus M. (AC); Santos, Mirentxu. (11/12). 2019. Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 116. ISSN 0027-8424. WOS (1)
- 10 Martinez, Victor G.; Munera-Maravilla, Ester; Bernardini, Alejandra; et al; Maria Paramio, Jesus (AC). (10/10). 2019. Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet FRONTIERS IN GENETICS. 10.
- 11 Durendez, E.; Calabuig-Farinas, S.; Suarez, C.; et al; Camps Herrero, C. J.2019. Exosomes in NSCLC as a source of biomarkers ANNALS OF ONCOLOGY. 30. ISSN 0923-7534.
- 12 Duenas, Marta; Perez-Figueroa, Andres; Oliveira, Carla; et al; Paramio, Jesus M.; Martinez-Fernandez, Monica. (8/9). 2019. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status SCIENTIFIC REPORTS. 9. ISSN 2045-2322.
- 13 Manso, L. M.; Lodewijk, I.; Bernal Hertfelder, E.; Suarez-Cabrera, C.; Garcia, J. L.; Wang, S.; Paramio, J. M.; Duenas, M.2019. Immune-related gene expression profiling after neoadjuvant chemotherapy (NACT) of ovarian high-grade serous carcinoma ANNALS OF ONCOLOGY. 30. ISSN 0923-7534.
- 14 Loras, Alba; Suarez-Cabrera, Cristian; Carmen Martinez-Bisbal, M.; Quintas, Guillermo; Paramio, Jesus M.; Martinez-Manez, Ramon; Gil, Salvador; Luis Ruiz-Cerdia, Jose. (5/8). 2019. Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer CANCERS. 11. ISSN 2072-6694. WOS (2)
- 15 Carretero-Gonzalez, Alberto; Homet Moreno, Blanca; Duenas, Marta; et al; Paramio, Jesus M.2019. Potential markers of response and resistance to programmed cell death-1 blockade in first-line therapy of cisplatin-ineligible advanced urothelial cancer.JOURNAL OF CLINICAL ONCOLOGY. 37. ISSN 0732-183X.
- 16 Francisco Lorenzo-Martin, L.; Citterio, Carmen; Menacho-Marquez, Mauricio; et al; Paramio, Jesus M.; Bustelo, Xose R.(15/16). 2019. Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanisms ONCOGENE. 38. ISSN 0950-9232. WOS (3)
- 17 Lodewijk, Iris; Duenas, Marta; Rubio, Carolina; et al; Paramio, Jesus M. (AC); Suarez-Cabrera, Cristian. (8/9). 2018. Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 19. ISSN 1422-0067. WOS (13)

- 18 Suarez-Cabrera, Cristian; Quintana, Rita M.; Bravo, Ana; et al; Paramio, Jesus M.; Navarro, Manuel. (7/12). 2017. A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer *CANCER RESEARCH*. 77. ISSN 0008-5472. WOS (12)
- 19 Martinez, Victor G.; Rubio, Carolina; Martinez-Fernandez, Monica; et al; Paramio, Jesus M.; Duenas, Marta. (16/18). 2017. BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer *CLINICAL CANCER RESEARCH*. 23. ISSN 1078-0432. WOS (21)
- 20 de Lena, Pelayo G.; Paz-Gallardo, Abel; Paramio, Jesus M. (AC); Garcia-Escudero, Ramon. (3/4). 2017. Clusterization in head and neck squamous carcinomas based on lncRNA expression: molecular and clinical correlates *CLINICAL EPIGENETICS*. 9. ISSN 1868-7075. WOS (8)
- 21 Feber, Andrew; Dhami, Pawan; Dong, Liqin; et al; Paramio, Jesus M.; Kelly, John D.(20/23). 2017. UroMark-a urinary biomarker assay for the detection of bladder cancer *CLINICAL EPIGENETICS*. 9. ISSN 1868-7083. WOS (30)
- 22 de Velasco, Guillermo; Trilla-Fuertes, Lucia; Gamez-Pozo, Angelo; et al; Paramio, Jesus M.; Castellano, Daniel. (15/17). 2017. Urothelial cancer proteomics provides both prognostic and functional information *SCIENTIFIC REPORTS*. 7. ISSN 2045-2322. WOS (5)
- 23 Puente, Javier; Lainez, Nuria; Duenas, Marta; et al; Paramio, Jesus. 2016. Integrated analysis of mRNA and miRNA to unravel novel mechanisms of sunitinib long term response in mRCC.*JOURNAL OF CLINICAL ONCOLOGY*. 34. ISSN 0732-183X.
- 24 Martinez-Fernandez, Monica; Duenas, Marta; Feber, Andrew; et al; Paramio, Jesus M. (AC). (16/16). 2015. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer *ONCOTARGET*. 6. WOS (26)
- 25 Martinez-Fernandez, Monica; Feber, Andrew; Duenas, Marta; et al; Paramio, Jesus M. (AC). (15/15). 2015. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer *CLINICAL EPIGENETICS*. 7. ISSN 1868-7075. WOS (42)
- 26 Maraver, Antonio; Fernandez-Marcos, Pablo J.; Cash, Timothy P.; et al; Paramio, Jesus M.; Serrano, Manuel. (16/18). 2015. NOTCH pathway inactivation promotes bladder cancer progression *JOURNAL OF CLINICAL INVESTIGATION*. 125. ISSN 0021-9738. WOS (41)
- 27 Duenas, Marta; Martinez-Fernandez, Monica; Garcia-Escudero, Ramon; et al; Paramio, Jesus M. (AC). (16/16). 2015. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors *MOLECULAR CARCINOGENESIS*. 54. ISSN 0899-1987. WOS (24)
- 28 Santos, Mirentxu; Martinez-Fernandez, Monica; Duenas, Marta; et al; Paramio, Jesus M. (AC). (21/21). 2014. In Vivo Disruption of an Rb-E2F-Ezh2 Signaling Loop Causes Bladder Cancer *CANCER RESEARCH*. 74. ISSN 0008-5472. WOS (42)
- 29 Saiz-Ladera, C.; Lara, M. F.; Garin, M.; et al; Paramio, J. M. (AC). (12/12). 2014. p21 suppresses inflammation and tumorigenesis on pRB-deficient stratified epithelia *ONCOGENE*. 33. ISSN 0950-9232. WOS (9)
- 30 Costa, C.; Santos, M.; Martinez-Fernandez, M.; Duenas, M.; Lorz, C.; Garcia-Escudero, R.; Paramio, J. M. (AC). (7/7). 2013. E2F1 loss induces spontaneous tumour development in Rb-deficient epidermis *ONCOGENE*. 32. ISSN 0950-9232. WOS (14)
- 31 Menacho-Marquez, Mauricio; Garcia-Escudero, Ramon; Ojeda, Virginia; et al; Paramio, Jesus M.; Bustelo, Xose R.(9/10). 2013. The Rho Exchange Factors Vav2 and Vav3 Favor Skin Tumor Initiation and Promotion by Engaging Extracellular Signaling Loops *PLOS BIOLOGY*. 11. ISSN 1544-9173. WOS (22)
- 32 Bornachea, Olga; Santos, Mirentxu; Belen Martinez-Cruz, Ana; et al; Paramio, Jesus M.2012. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours *SCIENTIFIC REPORTS*. 2. ISSN 2045-2322. WOS (61)
- 33 Ganuza, Miguel; Saiz-Ladera, Cristina; Canamero, Marta; et al; Paramio, Jesus M.; Barbacid, Mariano. (8/10). 2012. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion *EMBO JOURNAL*. 31. ISSN 0261-4189. WOS (42)
- 34 Castellano, Daniel E.; Sepulveda, Juan; Martinez-Fernandez, Monica; et al; Paramio, Jesus. 2012. PIK3CA gene alterations in bladder cancer: Analysis of correlative series of transurethral resection (TUR)-Correlation with grade histology and tumor size *JOURNAL OF CLINICAL ONCOLOGY*. 30. ISSN 0732-183X.

- 35 Citterio, Carmen; Menacho-Marquez, Mauricio; Garcia-Escudero, Ramon; Larive, Romain M.; Barreiro, Olga; Sanchez-Madrid, Francisco; Paramio, Jesus M.; Bustelo, Xose R.(7/8). 2012. The Rho Exchange Factors Vav2 and Vav3 Control a Lung Metastasis-Specific Transcriptional Program in Breast Cancer Cells SCIENCE SIGNALING. 5. ISSN 1937-9145. WOS (64)
- 36 Pippa, R.; Espinosa, L.; Gundem, G.; et al; Paramio, J. M.; Bachs, O.(12/14). 2012. p27(Kip1) represses transcription by direct interaction with p130/E2F4 at the promoters of target genes ONCOGENE. 31. ISSN 0950-9232. WOS (38)

### C.3. Research projects and contracts

- 1 **Project.** BlaDimiR. Optimización de un dispositivo electrónico para diagnóstico y pronóstico de respuesta a BCG en biopsia líquida para pacientes de cáncer de vejiga.. Instituto de Salud Carlos III DTS20/00043. (CIEMAT and Hosp 12 de Octubre). 01/01/2021-31/12/2022. 64.900 €.
- 2 **Project.** Improving immunotherapy throu epigenetic inhibitors in bladder cancer. Ministry of Science and technology PID2019-110758RB-I00. (CIEMAT and Hosp "12 de Octubre"). 01/09/2020-01/07/2022. 387.200 €.
- 3 **Project.** New Disease Models and Diagnostic Tools for Head And Neck Squamous Cell Carcinoma in Fanconi Anemia Patients. Fundación Anemia de Fanconi. (FUNDACION PARA LA INVEST. BIOMEDICA DEL HOSPITAL UNIV. DOCE DE OCTUBRE). 01/09/2018-31/12/2020. 150.000 €.
- 4 **Project.** Caracterización genómica e inmunológica de tumores renales hereditarios. SEOM. (Hospital Universitario 12 de Octubre). 01/01/2018-31/12/2020. 30.000 €.
- 5 **Project.** Evaluation of miRNAs and miRNA derived peptides (miPEPs) in liquid biopsies for bladder cancer diagnosis, prognosis and BCG treatment response. Ferring Pharmaceuticals Innovation Grants. (FUNDACION PARA LA INVEST. BIOMEDICA DEL HOSPITAL UNIV. DOCE DE OCTUBRE). 01/01/2019-31/12/2019. 108.000 €.
- 6 **Project.** Understanding Bladder Cancer Through Genetically Engineered Mouse Models Of Preclinical Application SAF2015-66015-R. MINECO. Jesús M Paramio. (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas). 2016-31/12/2019. 363.000 €. Principal investigator.
- 7 **Project.** CIBER ONC. Instituto de Salud Carlos III. Jesus M Paramio González. (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas). 01/01/2017-31/12/2018. 130.000 €.
- 8 **Project.** Discovery, Validation and Implementation of Biomarkers for Precision Oncology ISCIII PIE15/00081. Instituto de Salud Carlos III. Luis Paz Ares. (FUNDACION PARA LA INVEST. BIOMEDICA DEL HOSPITAL UNIV. DOCE DE OCTUBRE). 2016-31/12/2018. 1.083.225 €. WP Leader.
- 9 **Contract.** Phase Ib trial of Atezolizumab and BCG in high risk BCG naïve non-muscle invasive bladder cancer (NMIBC) patients 01/01/2020-01/01/2022. 740.000 €.
- 10 **Contract.** A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based chemotherapy Tesaro & Ipsen. Jesus M Paramio. From 2018.
- 11 **Contract.** Prognostic and predictive value of immune genomic signatures in correlation with homologous recombination defficiency in high grade serous ovarian cancer Tesaro. Jesus M Paramio. 2018-01/01/2019.
- 12 **Contract.** Genomic characterization of extreme responders to identify the basis for Vinflunine Sensitivity in Bladder Cancer patients. Jesus M Paramio. From 2017.
- 13 **Contract.** Analysis of Palbociclib effects in bladder cancer cell lines Jesús M Paramio. 2015-01/01/2016. 34.000 €.